By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Being a layperson in bioproduction, I wanted to know more about the concept and reality of continuous manufacturing (CM), and especially why a company would elect to build its own CM capability in-house. A natural candidate for educating me is an advocate for companies using CM in whatever setting fit their needs. She is Patricia (Trish) Hurter, a pharma manufacturing veteran and now CEO of Lyndra Therapeutics.